Bone Metabolism

Latest News

Shorter Sleep Duration Associated With Osteoporosis in Postmenopausal Women

By

Hannah Dellabella

Epidemiologic data indicate that shorter sleep duration (≤5 hours per night) is associated with lower bone mineral density in postmenopausal women.

Cardiovascular Effects of Denosumab and Romosozumab in Osteoporosis

By

Amit Akirov, MD

In a meta-analysis, researchers aimed to explore the association between denosumab and romosozumab and cardiovascular risk in patients with primary osteoporosis.

Fracture Risk, BMD Improvement With Abaloparatide Plus Alendronate in Osteoporosis, OA

By

Rachael Beairsto

In this post hoc analysis, researchers evaluated the efficacy and safety of abaloparatide followed by alendronate vs placebo followed by alendronate in a subgroup of patients with osteoarthritis.

The Independent Role of Elevated Serum Calcium on Bone Metabolism

By

Amit Akirov, MD

Elevated calcium levels may lead to suboptimal growth of bone, according to the study’s findings.

Large BMD Gains With Second Course of Romosozumab in Postmenopausal Women

By

Laurell Haapanen

A second course of romosozumab led to either gains in or maintenance of bone mineral density in postmenopausal women who were 12 months off treatment or transitioning from denosumab.

Meta-Analysis: Nonbisphosphonates Reduce Fracture Risk in Osteoporosis

By

Hannah Dellabella

Nonbisphosphonates, including denosumab, raloxifene, romosozumab, and teriparatide, significantly reduce vertebral fractures and benefit femoral neck bone mineral density compared with placebo.

Baseline MRI Inflammation Not a Determinant of BMD Loss in Spondyloarthritis

By

Endocrinology Advisor Contributing Writer

Investigators evaluated the effect of magnetic resonance imaging baseline inflammation on changes in bone mineral density over the course of 5 years in patients with early spondyloarthritis.

Marked Heterogeneity in Osteoporosis Treatment Preferences Found Among Patients

By

Hannah Dellabella

In patients with osteoporosis, treatment preference varies but is not related to specific patient characteristics.

Risperidone Treatment Not Linked to Osteoporosis Fracture Risk

By

Endocrinology Advisor Contributing Writer

Risperidone treatment may not be associated with an increased risk for osteoporosis-related fractures compared with other atypical antipsychotic medications, according to study results published in Acta Psychiatrica Scandinavica. Researchers conducted a nationwide cohort study comparing the risk for osteoporosis-related fractures in patients treated with risperidone vs other atypical and typical antipsychotic medications. Investigators specifically evaluated…

Bone Characteristics by QCT in Patients With Normal vs Abnormal Glucose Tolerance

By

Amit Akirov, MD

Diagnosis of osteoporosis based on QCT analysis is more common in patients with diabetes and impaired glucose tolerance compared with patients with normal glucose tolerance.

Changes in Bone Strength and Density After Roux-en-Y Gastric Bypass

By

Amit Akirov, MD

In patients who underwent Roux-en-Y gastric bypass, bone material strength index was improved 1 year after surgery despite an increase in bone turnover and lower overall areal bone mineral density.